The life expectancy of a 50 year old man is approximately 30 years. Since some of the patients who would receive Aionios are older than 50, assume a 20 year average life expectancy for this group. The cost of the drug is $1,000 per year, taken for the rest of the patients life. The medical costs of having a heart attack have an expected value of $500,000. (Assume a discount rate of 0%.)

Question 3: Looking only at the financial costs, is it worthwhile for a patient in the target group to take Aionios?